B BioPulse
Regulatory Sep 18, 2026 · 1 min read · 33,982 views

FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data

S

Sophia Reyes

Editorial · Sep 18, 2026

FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data

Plus news about Biokin, Bristol Myers Squibb, Grünenthal and Johnson & Johnson. FDA approves ataxia-telangiectasia treatment: The agency approved the rare genetic disease treatment Aqneursa from the privately held biotech IntraBio

Read Original Source Back to Feed

← Previous

Vertex aims for broad kidney disease label ahead of key readout next year

Next →

Pentagon defends designating WuXi AppTec as Chinese military company

Related Reading

Updated: Ultragenyx's new gene therapy will cost $3.95M
Regulatory

Updated: Ultragenyx's new gene therapy will cost $3.95M

Sep 24, 2026

Roivant's road to a potential blockbuster begins with FDA approval for Lisraya
Regulatory

Roivant's road to a potential blockbuster begins with FDA approval for Lisraya

Sep 22, 2026

FDA faces questions on 'America First' provisions in latest user fee agreement
Regulatory

FDA faces questions on 'America First' provisions in latest user fee agreement

Sep 21, 2026